ADMA Biologics Announces Financial Results Call
ADMA Biologics, Inc. (Nasdaq: ADMA) is gearing up to reveal its second quarter financial performance for 2025 on August 6, following the closure of U.S. trading markets. The management team of ADMA is excited to host a live conference call at 4:30 p.m. ET on the day of the announcement to provide insights into its financial results as well as current updates on the Company.
Details on Participation for the Conference Call
For those looking to participate in the conference call, early registration is essential to ensure seamless access. Registrants will receive dial-in numbers and a unique PIN necessary for entry. It’s recommended to join the call about 10 minutes early, although attendees are welcome to dial in anytime during the session. Individuals who prefer to listen rather than ask questions will have the option to join the live audio webcast which will also be available.
Accessing Archived Event Information
For anyone unable to attend the live event, an archived recording will be accessible under the ‘Events & Webcasts’ section in the investor relations segment of ADMA's website, making it easy to catch up on what was discussed at a later time.
ADMA Biologics: Company Overview
ADMA Biologics is recognized as a U.S.-based biopharmaceutical entity specializing in the manufacturing, marketing, and development of specialty biologics. Their focus is dedicated to serving immunodeficient patients vulnerable to infections and others who are at risk for specific infectious diseases. The Company is proud to manufacture and market a trio of FDA-approved plasma-derived biologics that address immune deficiencies: ASCENIV™, BIVIGAM, and NABI-HB. These products are specifically designed to bolster patients' immune systems against several diseases.
Innovative Developments in Biologics
In addition to its existing product line, ADMA is also at the forefront of developing SG-001, an investigational hyperimmune globulin designed to target pneumococcal infections. Through its FDA-licensed facility in Boca Raton, Florida, ADMA ensures high-quality production of its immune globulin products from its plasma fractionation and purification processes.
Commitment to Quality and Compliance
ADMA’s commitment extends beyond just the manufacturing of their biologics; they operate plasma collection centers across the U.S., ensuring a consistent supply of high-quality plasma for their production needs. Their strict compliance with FDA regulations underscores their dedication to safety and efficacy in their products, which is vital for the health of their patient population.
Contact Information for Investors
For inquiries regarding investment opportunities or company information, interested parties can reach out to ADMA’s investor relations team. They are available to address any questions or provide additional insights into the Company’s operations and performance.
Frequently Asked Questions
1. When is ADMA Biologics expected to report financial results?
ADMA Biologics will report its second quarter 2025 financial results on August 6, following the market closure.
2. How can I listen to the conference call?
Participants can join the conference call by registering in advance to obtain dial-in numbers and a unique PIN.
3. Will an archived version of the call be available?
Yes, an archived replay of the event will be made available under the ‘Events & Webcasts’ section of the Company’s investor website.
4. What products does ADMA Biologics offer?
ADMA Biologics manufactures several FDA-approved plasma-derived products, including ASCENIV™, BIVIGAM, and NABI-HB.
5. How does ADMA ensure quality in its products?
ADMA operates FDA-licensed facilities for plasma fractionation and purification, maintaining high standards to produce safe and effective biologics.
